Tekla Healthcare Investors Stock Price To Sales
| HQH Stock | USD 17.18 0.54 3.05% |
Tekla Healthcare Investors fundamentals help investors to digest information that contributes to Tekla Healthcare's financial success or failures. It also enables traders to predict the movement of Tekla Stock. The fundamental analysis module provides a way to measure Tekla Healthcare's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tekla Healthcare stock.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 85.91 | 112.64 |
Tekla | Price To Sales |
Tekla Healthcare Investors Company Price To Sales Analysis
Tekla Healthcare's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Tekla Healthcare Price To Sales | 89.98 X |
Most of Tekla Healthcare's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tekla Healthcare Investors is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tekla Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Tekla Healthcare is extremely important. It helps to project a fair market value of Tekla Stock properly, considering its historical fundamentals such as Price To Sales. Since Tekla Healthcare's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tekla Healthcare's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tekla Healthcare's interrelated accounts and indicators.
Click cells to compare fundamentals
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Tekla Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Tekla Healthcare Investors has a Price To Sales of 89 times. This is much higher than that of the Capital Markets sector and notably higher than that of the Financials industry. The price to sales for all United States stocks is notably lower than that of the firm.
Tekla Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tekla Healthcare's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tekla Healthcare could also be used in its relative valuation, which is a method of valuing Tekla Healthcare by comparing valuation metrics of similar companies.Tekla Healthcare is currently under evaluation in price to sales category among its peers.
Tekla Healthcare Current Valuation Drivers
We derive many important indicators used in calculating different scores of Tekla Healthcare from analyzing Tekla Healthcare's financial statements. These drivers represent accounts that assess Tekla Healthcare's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Tekla Healthcare's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 904.6M | 1.1B | 818.1M | 768.8M | 691.9M | 516.8M | |
| Enterprise Value | 907.1M | 1.1B | 826.6M | 768.8M | 691.9M | 518.0M |
Tekla Healthcare ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tekla Healthcare's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tekla Healthcare's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Tekla Fundamentals
| Return On Equity | 0.0734 | ||||
| Return On Asset | -7.0E-4 | ||||
| Profit Margin | 7.31 % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | 897.06 M | ||||
| Shares Outstanding | 50.62 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 26.29 % | ||||
| Number Of Shares Shorted | 74.35 K | ||||
| Price To Earning | 3.38 X | ||||
| Price To Book | 0.89 X | ||||
| Price To Sales | 89.98 X | ||||
| Revenue | 58.12 M | ||||
| Gross Profit | 8.27 M | ||||
| EBITDA | 56.33 M | ||||
| Net Income | 56.33 M | ||||
| Cash And Equivalents | 62 | ||||
| Total Debt | 1.15 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | 19.91 X | ||||
| Cash Flow From Operations | (65.41 M) | ||||
| Short Ratio | 0.68 X | ||||
| Earnings Per Share | 1.31 X | ||||
| Beta | 0.74 | ||||
| Market Capitalization | 897.07 M | ||||
| Total Asset | 932.49 M | ||||
| Retained Earnings | 5.97 M | ||||
| Annual Yield | 0.14 % | ||||
| Five Year Return | 8.90 % | ||||
| Net Asset | 932.49 M | ||||
| Last Dividend Paid | 1.66 |
About Tekla Healthcare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tekla Healthcare Investors's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tekla Healthcare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tekla Healthcare Investors based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:Check out Tekla Healthcare Piotroski F Score and Tekla Healthcare Altman Z Score analysis. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.145 | Dividend Share 1.66 | Earnings Share 1.31 | Revenue Per Share 0.197 | Quarterly Revenue Growth (0.06) |
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.